Takeda sets sights on obesity with global Amylin tie-up
This article was originally published in Scrip
Executive Summary
Takeda is taking a decisive step into the obesity sector through a wide-ranging global alliance with Amylin Pharmaceuticals, which could eventually be worth more than $1 billion to the US firm.